Abstract
Objective: This project aims to investigate the anti-angiogenic effects of chemically modified heparins, specifically 6-desulfated heparin, in combination with bevacizumab, an anti-VEGF monoclonal antibody. The study will be conducted on human endothelial cells, specifically the ECV304 cell line, which is widely used in angiogenesis research due to its representative characteristics of en…